메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Hirozumi Sano (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Ryoji Kobayashi (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Satoru Matsushima (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Daiki Hori (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Masato Yanagi (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Koya Kodama (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Daisuke Suzuki (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa) Kunihiko Kobayashi (Department of Hematology/Oncology for Children and Adolescents Sapporo Hokuyu Hospital Sapporo Japa)
저널정보
대한소아혈액종양학회 Clinical Pediatric Hematology-Oncology Clinical Pediatric Hematology-Oncology Vol.28 No.2
발행연도
2021.10
수록면
75 - 83 (9page)
DOI
10.15264/cpho.2021.28.2.75

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Febrile neutropenia (FN) remains an important complication in pedia-tric cancer patients. The present study compared the efficacy of meropenem (MEPM) and piperacillin/tazobactam (PIPC/TAZ) with or without intravenous immunoglobulin (IVIG) as second-line therapy for FN in pediatric patients.Methods: As first-line treatment for FN, 394 episodes in 99 patients were randomly assigned to receive PIPC/TAZ (360 mg/kg/day, maximum 18 g/day) or MEPM (120 mg/ kg/day, maximum 3 g/day). Eighty-four episodes in 42 patients were judged as fail-ures, and, thus, were enrolled for second-line treatment. In second-line treatment, antibiotics were switched to MEPM or PIPC/TAZ, and episodes were further random-ized for treatment with or without concomitant IVIG at 100 mg/kg/day (maximum 5 g/day) for 3 consecutive days.Results: The total success rate of second-line treatment was 50.0% (52.0% in PIPC/ TAZ and 47.2% in MEPM with or without IVIG, P=0.826). The success rates of patients treated with (IVIG+ group) and without IVIG (IVIG? group) were 53.8 and 46.7%, respectively (P=0.662). In the IVIG+ group, the success rate of patients younger than 8 years old was 78.6%, which was significantly higher than that of those aged 8 years and older (40.0%, P=0.043).Conclusion: PIPC/TAZ and MEPM were equally effective as second-line treatment. Concomitant IVIG was also effective, particularly in patients younger than 8 years.

목차

등록된 정보가 없습니다.

참고문헌 (21)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0